Cynthia Butitta Net Worth

The estimated Net Worth of Cynthia M Butitta is at least $4.15 Million dollars as of 12 August 2020. Ms. Butitta owns over 83,876 units of UroGen Pharma Ltd stock worth over $1,158,328 and over the last 8 years she sold URGN stock worth over $2,653,539. In addition, she makes $335,198 as Independent Director at UroGen Pharma Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Butitta URGN stock SEC Form 4 insiders trading

Cynthia has made over 23 trades of the UroGen Pharma Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 83,876 units of URGN stock worth $369,893 on 12 August 2020.

The largest trade she's ever made was exercising 83,876 units of UroGen Pharma Ltd stock on 12 August 2020 worth over $369,893. On average, Cynthia trades about 9,300 units every 40 days since 2016. As of 12 August 2020 she still owns at least 83,876 units of UroGen Pharma Ltd stock.

You can see the complete history of Ms. Butitta stock trades at the bottom of the page.

Cynthia Butitta biography

Cynthia M. Butitta is Independent Director of the Company. Ms. Butitta served as Chief Financial Officer of Kite Pharma Inc. from January 2014 to May 2016 and as Chief Operating Officer from March 2014 to September 2017. From May 2011 to December 2012, she was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company. Prior to that, Ms. Butitta served as Chief Operating Officer of Telik, Inc., a biopharmaceutical company, from March 2001 to December 2010 and as its Chief Financial Officer from August 1998 to December 2010. Ms. Butitta also served as Principal Accounting Officer of Telik, Inc. until December 2010. She has served as a Director of Autolus, Ltd., a biotechnology company, since March 2018. Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin, and an M.B.A. degree in Finance from the University of Wisconsin, Madison. Our Board believes Ms. Butitta’s financial knowledge and experience qualifies her to serve on our board of directors.

What is the salary of Cynthia Butitta?

As the Independent Director of UroGen Pharma Ltd, the total compensation of Cynthia Butitta at UroGen Pharma Ltd is $335,198. There are 7 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.

How old is Cynthia Butitta?

Cynthia Butitta is 65, she's been the Independent Director of UroGen Pharma Ltd since 2017. There are 1 older and 14 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.

What's Cynthia Butitta's mailing address?

Cynthia's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.

Insiders trading at UroGen Pharma Ltd

Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun, and Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.

What does UroGen Pharma Ltd do?

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.

Complete history of Ms. Butitta stock trades at UroGen Pharma Ltd and Olema Pharmaceuticals

UroGen Pharma Ltd executives and stock owners

UroGen Pharma Ltd executives and other stock owners filed with the SEC include:

• Elizabeth Barrett,
  President, Chief Executive Officer, Director
• Elizabeth A. Barrett,
  Pres, CEO & Director
• Mark Schoenberg,
  Chief Medical Officer
• Ron Bentsur,
  Advisor
• Dr. Mark P. Schoenberg,
  Chief Medical Officer
• Arie Belldegrun,
  Independent Chairman of the Board
• Jason Drew Smith,
  Gen. Counsel & Chief Compliance Officer
• Cynthia Butitta,
  Independent Director
• Kathryn Falberg,
  Independent Director
• Stuart Holden,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Fred Cohen,
  Independent Director
• Shawn Tomasello,
  Independent Director
• Molly Henderson CPA, MBA,
  Chief Financial Officer
• Elyse Seltzer,
  Chief Development Officer
• Polly Murphy,
  Chief Business Officer
• Jeff Bova,
  Chief Commercial Officer
• Jason Smith,
  Chief Compliance Officer, General Counsel
• Jim Ottinger,
  Executive Vice President, Regulatory Affairs and Quality
• Marina Konorty,
  Executive Vice President, Research & Development and Technical Operations
• Molly Henderson,
  Chief Financial Officer, Principal Accounting Officer
• James Ottinger R.ph.,
  Exec. VP of Regulatory Affairs & Quality
• Jeffrey Bova M.B.A.,
  Chief Commercial Officer
• Dr. Sari Prutchi-Sagiv Ph.D.,
  Marketing Director
• Eric Van Zanten,
  Sr. Director of Communications
• Jason Smith,
  Gen. Counsel & Chief Compliance Officer
• Sara Blum Sherman,
  Sr. Director of Investor Relations
• James A. Jr. Robinson,
  Director
• Investments Iv, L.P.Pro Que...,
  
• Stephen Mullennix,
  Chief Operating Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Leana Wen,
  Director
• Dong Kim,
  Chief Financial Officer
• Daniel George Wildman,
  Director